doripenem has been researched along with levofloxacin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 7 (31.82) | 2.80 |
| Authors | Studies |
|---|---|
| Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
| Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W | 1 |
| Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R | 1 |
| Aquino, EE; León, CF; Otero, DM; Robledo, IE; Santana, JL; Santé, MI; Vázquez, GJ | 1 |
| Flamm, R; Friedland, I; Kaniga, K; Lee, M; Redman, R; Tong, SY | 1 |
| Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
| Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R | 1 |
| Davies, TA; He, W; Lynch, AS; Queenan, AM | 1 |
| Kurtinecz, M; Li, G; Mitrani-Gold, FS; Mundy, LM; Singh, KP; Tomayko, JF; Wetherington, J | 1 |
| Crandon, JL; Nicolau, DP; Nordmann, P; Wiskirchen, DE | 1 |
| Mataraci-Kara, E; Ozbek Celik, B; Yilmaz, M | 1 |
| Pliska, NN | 1 |
| Istanbullu Tosun, A; Mataraci Kara, E; Özbek Çelik, B; Yilmaz, M | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 2 |
| Chen, YH; Chen, YS; Cheng, SH; Hsueh, PR; Ko, WC; Lee, CM; Lee, WS; Lee, YL; Lin, CN; Lin, CY; Liu, CP; Lu, MC; Lu, PL; Shao, PL; Sheng, WH; Shi, ZY; Tang, HJ; Tsai, YT; Tseng, SH; Wang, FD; Wang, LS; Wu, TS; Yen, MY | 1 |
| Baba, T; Boucher, HW; Chambers, HF; Collyar, D; Dai, W; Doernberg, SB; Evans, SR; Fowler, VG; Gelone, SP; Hamasaki, T; Hill, C; Holland, TL; Howard-Anderson, J; Kinamon, T; Mariano, D; Nambiar, S; Rubin, D | 1 |
| Enokiya, T; Imai, H; Kato, T; Morikawa, Y; Okuda, M | 1 |
2 review(s) available for doripenem and levofloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Clinical Trials as Topic; Databases, Bibliographic; Doripenem; Drug Combinations; Female; Humans; Imipenem; Levofloxacin; Male; Research Design; Treatment Outcome; Urinary Tract Infections | 2013 |
3 trial(s) available for doripenem and levofloxacin
| Article | Year |
|---|---|
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prospective Studies; Pyelonephritis; Urinary Tract Infections | 2009 |
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pyelonephritis; Urinary Tract Infections | 2009 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Urinary Tract Infections | 2010 |
17 other study(ies) available for doripenem and levofloxacin
| Article | Year |
|---|---|
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States | 2007 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
Detection of KPC in Acinetobacter spp. in Puerto Rico.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; beta-Lactam Resistance; beta-Lactamases; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance; Puerto Rico | 2010 |
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Ciprofloxacin; Clinical Trials, Phase III as Topic; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Global Health; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence | 2010 |
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Mice; Ofloxacin; Pneumonia, Ventilator-Associated; Random Allocation; Survival Analysis | 2013 |
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Disease Models, Animal; Doripenem; Ertapenem; Humans; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit.
Topics: Carbapenems; Colistin; Doripenem; Dose-Response Relationship, Drug; Drug Combinations; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Minocycline; Rifampin; Tigecycline; Tobramycin | 2014 |
Pseudomonas Aeruginosa as the Main Causative Agent of Osteomyelitis and its Susceptibility to Antibiotics.
Topics: Amikacin; Anti-Bacterial Agents; Chronic Disease; Doripenem; Gentamicins; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2020 |
Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Colistin; Doripenem; Drug Combinations; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Real-Time Polymerase Chain Reaction; Tigecycline; Tobramycin | 2020 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Levofloxacin; Linezolid; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; Taiwan; Vancomycin | 2022 |
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials.
Topics: Anti-Bacterial Agents; Doripenem; Humans; Imipenem; Levofloxacin; Urinary Tract Infections | 2023 |
UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Continuous Renal Replacement Therapy; Doripenem; Humans; Levofloxacin; Linezolid; Meropenem; Tandem Mass Spectrometry | 2023 |
Sequestration of Antimicrobial Agents in Xcoating and Heparin-Coated Extracorporeal Membrane Oxygenation Circuits: An In Vitro Study.
Topics: Animals; Anti-Infective Agents; Cattle; Cefazolin; Daptomycin; Doripenem; Extracorporeal Membrane Oxygenation; Heparin; Humans; Levofloxacin | 2023 |